Anticipation of pharmacotherapeutic problems prior to allo stem cell transplantation in patients with co-morbidities (SFGM-TC)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) frequently involves patients with multiple co-morbidities. The drugs prescribed for these conditions may lead to complications during the transplant procedure, either through their mechanism of action, their adverse reaction profile or the risk of pharmacological interactions with the drugs prescribed for the allo-HSCT procedure and its complications. Therefore, each patient's drug-related risks must be assessed prior to allo-HSCT. Various therapeutic decisions may be considered to limit the occurrence of complications. The aim of this study is to propose a methodology for anticipating these issues prior to allo-HSCT and to propose a consensual therapeutic approach for therapeutic situations commonly encountered in the context of hematopoietic stem cell allogeneic transplantation. We specifically address cardiovascular, psychotropic drugs, and anti-infectives medications, antidiabetics and anticoagulants.

Published by Bulletin du cancer, 2026. The guideline itself is at the source linked here.

doi.org/10.1016/j.bulcan.2025.04.014